Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.77 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycerin SCHEMBL722087 | 1.00 | USP2 (0.77) | USP2HTTMEN1KMT2ATHRB | |
| Glycerin SCHEMBL16289663 | 1.00 | USP2 (0.77) | USP2HTTMEN1KMT2ATHRB | |
| Glycerin SCHEMBL4257733 | 1.00 | USP2 (0.77) | USP2HTTMEN1KMT2ATHRB | |
| Glycerin SCHEMBL2411393 | 1.00 | USP2 (0.77) | USP2HTTMEN1KMT2ATHRB | |
| Glycerin SCHEMBL3092973 | 1.00 | USP2 (0.77) | USP2HTTMEN1KMT2ATHRB | |
| Glycerin SCHEMBL466711 | 1.00 | USP2 (0.77) | USP2HTTMEN1KMT2ATHRB | |
| Glycerin SCHEMBL18140350 | 1.00 | USP2 (0.77) | USP2HTTMEN1KMT2ATHRB | |
| Glycerin SCHEMBL18140847 | 1.00 | USP2 (0.77) | USP2HTTMEN1KMT2ATHRB | |
| Glycerin SCHEMBL722452 | 1.00 | USP2 (0.77) | USP2HTTMEN1KMT2ATHRB | |
| Glycerin SCHEMBL10277135 | 1.00 | USP2 (0.77) | USP2HTTMEN1KMT2ATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6077896-A | COMPOSITION COMPRISING OXYALKYLENE POLYMER CONTAINING REACTIVE SILYL GROUPS, COMPOUND HAVING INTRAMOLECULAR ALPHA, BETA-DIOL OR ALPHA, GAMMA-DIOL STRUCTURE | KANEKA CORPORATION (JP) | 2000-06-20 | — | — | US | claimed |
| EP-2759581-B1 | CURABLE COMPOSITION AND CURED PRODUCT THEREOF | KANEKA CORP (JP) | 2018-01-24 | — | — | EP | disclosed |
| US-9593271-B2 | Curable composition and cured product thereof | KANEKA CORPORATION (JP) | 2017-03-14 | — | — | US | disclosed |
| US-20160009619-A1 | POLYGLYCERIN DIALKYL OR ALKENYL ETHER, AND COSMETIC COMPOSITION CONTAINING SAME | DAICEL CORPORATION (JP) | 2016-01-14 | — | — | US | disclosed |
| EP-2813483-A1 | POLYGLYCERIN DIALKYL OR ALKENYL ETHER, AND COSMETIC COMPOSITION CONTAINING SAME | Daicel Corporation (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-20140288222-A1 | CURABLE COMPOSITION AND CURED PRODUCT THEREOF | KANEKA CORPORATION (JP) | 2014-09-25 | — | — | US | disclosed |
| EP-2759581-A1 | CURABLE COMPOSITION AND CURED PRODUCT THEREOF | Kaneka Corporation (JP) | 2014-07-30 | — | — | EP | disclosed |
| EP-2484435-A1 | GEL-LIKE COMPOSITION | Daicel Chemical Industries, Ltd. (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-20120178823-A1 | GEL-LIKE COMPOSITION | DAICEL CORPORATION (JP) | 2012-07-12 | — | — | US | disclosed |
| EP-2103298-A1 | Lamellar type liquid crystal composition for cosmetic | Daicel Chemical Industries, Ltd. (JP) | 2009-09-23 | — | — | EP | disclosed |
| JP-2009067735-A | COSMETIC FOR HAIR | MANDOM CORP | 2009-04-02 | — | — | JP | disclosed |
| US-20080234426-A1 | Curable Composition and Cured Object Thereof | KANEKA CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
| EP-1852472-A1 | CURABLE COMPOSITION AND CURED OBJECT THEREOF | Kaneka Corporation (JP) | 2007-11-07 | — | — | EP | disclosed |
| US-20060135709-A1 | Curing composition | KANEKA CORPORATION (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1637565-A1 | CURING COMPOSITION | KANEKA CORPORATION (JP) | 2006-03-22 | — | — | EP | disclosed |
| EP-0902042-B1 | Curable composition | KANEKA CORP (JP) | 2004-11-03 | — | — | EP | disclosed |
| US-6077896-A | COMPOSITION COMPRISING OXYALKYLENE POLYMER CONTAINING REACTIVE SILYL GROUPS, COMPOUND HAVING INTRAMOLECULAR ALPHA, BETA-DIOL OR ALPHA, GAMMA-DIOL STRUCTURE | KANEKA CORPORATION (JP) | 2000-06-20 | — | — | US | disclosed |
| EP-0902042-A1 | Curable composition | Kaneka Corporation (JP) | 1999-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009619-A1 | POLYGLYCERIN DIALKYL OR ALKENYL ETHER, AND COSMETIC COMPOSITION CONTAINING SAME | DEGS1, DAGLA, MGLL | USP2 1781/4885HTT 1986/4885MEN1 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.